List view / Grid view
Experimental Parkinson’s drug PRI-101 has shown promising preclinical results, effectively targeting and disassembling toxic α-synuclein protein aggregates that drive neurodegeneration.
Why do some targeted assays move smoothly from discovery to clinical practice while others stall? The answer often lies in the earliest design decisions, where choices about samples, platforms and data determine what is possible later.
To study the biological underpinnings of autism, researchers must examine the human brain itself. This article explores how Autism BrainNet supports this work through coordinated tissue donation and preservation.
Drug discovery has no shortage of powerful technologies, but the challenge now is making them work together. At SLAS Boston 2026, researchers and technology developers revealed how laboratories are connecting the entire experimental pipeline.
A major international study has discovered genetic similarities between cancers in cats and humans, potentially helping to inform future drugs that could benefit both species.
Complex diseases rarely have single targets. By focusing on transcription factor activity and disease signatures, Scripta Therapeutics is taking a different approach to identifying the drivers of pathology.
AI is moving from a supporting role into the core of drug discovery. By 2026, it is expected to shape how targets are chosen, how biology is analysed and how development decisions are made.
Drug-induced liver injury remains one of drug development’s most costly pitfalls. Now, AI and transcriptomics may offer a way to spot risks long before they reach patients.
Stress during pregnancy may disrupt the maternal gut-immune system, altering foetal brain development and revealing sex-specific vulnerabilities linked to neurodevelopmental risk
A new study suggests that a low-cost form of non-invasive prenatal screening could help clinicians identify pregnant women at highest risk of transmitting cytomegalovirus to their babies.
Seattle-based biotech company, Variant Bio, have launched Inference, an AI-powered genomics platform designed to accelerate drug discovery and identify genetically supported targets.
Procedural advances in IVF are reaching their biological limits. Reproductive biotech is now moving upstream, developing first in class therapeutics that target meiosis, gamete quality and implantation biology as druggable mechanisms in early discovery.
The DMTA cycle depends on clear data flow, yet most labs still work across disconnected systems. Sean McGee, Director of Product at Certara, explains how better infrastructure and AI can help teams work faster and make decisions with more confidence.
Scientists have developed an experimental RNA-based drug, TY1, that repairs DNA, reduces scar tissue and could lead to new treatments for heart attacks and autoimmune diseases.
Every great leap in history started with a single, urgent need. Now AI is emerging as the next great engine of invention, transforming the future of medicine faster than ever imagined.
